Expired Tender Australia ICB TOT Ref. 17800709

Pharma 2017 - Anti-Infectives Tender Tender in Australia - 17800709

Tender notice from Australia, published on 31 Oct 2017.

Executive Summary

The QUEENSLAND HEALTH PHARMACEUTICALS CATEGORY has issued a Tender notice for the procurement of a Pharma 2017 - Anti-Infectives Tender in the Australia. This Tender notice was published on 31 Oct 2017 and is scheduled to close on 21 Nov 2017, with an estimated Tender value of Refer Document. Interested bidders can access detailed Tender information, eligibility criteria, and complete bidding documents by referencing TOT Ref No. 17800709, while the tender notice number is AntiInfect2017 and Register on the platform.

Key facts

Summary
Pharma 2017 - Anti-Infectives Tender
TOT Ref. No.
17800709
Document Ref. No.
AntiInfect2017
Country
Australia
Notice type
Tender
Competition
ICB
Publication date
31 Oct 2017
Bid deadline
21 Nov 2017
EMD
Refer Document
Tender value
Refer Document
Purchaser ownership
-
Financier
Self Financed

Purchaser details

Purchaser contact is for registered users

Login to see details

Tender details

The department of health (doh) is requesting offers of pricing for molecules within the pharmaceuticals therapeutic groups below:
drugs-general antiinfective-systemic use
depending on requirements these pharmaceuticals include all patent and generic presenations for the following:
abacavir
abacavir - lamivudine
abacavir - lamivudine - zidovudine
aciclovir
amikacin
adefovir
amikacin
amoxycillin
amoxicillin - clavulanic acid
amoxycillin - clavulanic acid
amphotericin (lipid complex)
amphotericin (liposomal)
amphotericin (sas)
ampicillin
anidulafungin
atazanavir
atazanavir - cobicistat
atovaquone
azithromycin
aztreonam
bedaquiline (sas)
benzylpenicillin
cefepime
cefotaxime
cefoxitin
ceftaroline fosamil
ceftazidime
ceftolozane - tazobactam
ceftriaxone
cefuroxime
cephalexin
cephazolin (cefazolin)
cidofovir (sas)
ciprofloxacin
ciprofloxacin - hydrocortisone
clarithromycin
clindamycin
clofazimine (sas)
colistin
colistin - powder for nebuliser soln (s5a)
cycloserine (sas)
daclatasvir
daptomycin
darunavir
darunavir - cobicistat
dicloxacillin
didanosine
dolutegravir
dolutegravir - abacavir - lamivudine
doxycycline
efavirenz
elbasvir - grazoprevir
ertapenem
erythromycin lactobionate
ethambutol
etravirine
faropenem (sas)
flucloxacillin
fluconazole
flucytosine
flucytosine (sas)
foscarnet
fosfomycin (sas)
ganciclovir
gentamicin
imipenem - cilastatin
isoniazid
itraconazole
lamivudine
lamivudine - zidovudine
ledipasvir / sofosbuvir
lincomycin
lopinavir - ritonavir
lopinavir - ritonavir
maraviroc
metronidazole
metronidazole 200mg/5ml
micafungin
nevirapine
nitrofurantoin
oseltamivir
para-aminosalicylic acid (sas)
paritaprevir / ritonavir / ombitasvir 75/50/12.5mg + dasabuvir 250mg
paritaprevir / ritonavir / ombitasvir 75/50/12.5mg + dasabuvir 250mg + ribavirin 600mg
palivizumab
peginterferon alfa 2a
penicillin benzathine
piperacillin - tazobactam
posaconazole
posaconazole 18mg/ml
pristinamycin (sas)
pyrazinamide (sas)
raltegravir
ribavirin
rifabutin
rifampicin
rifaximin
rilpivirin

Documents

Tender Notice
Login to view

Australia Public Procurement Intelligence

Frequently asked questions

The bid deadline for Pharma 2017 - Anti-Infectives Tender was 21 Nov 2017. Bidding is closed.

This tender has been issued by QUEENSLAND HEALTH PHARMACEUTICALS CATEGORY in Australia.

The tender value is not disclosed; please refer to the tender document. EMD / bid security details are provided in the tender document.

This tender is Self Financed

The tender notice and related documents are listed in the Documents section above. Select a document to view or download it. Please log in or register to access the documents. If you cannot find additional documents in the Documents section, please log in to your account and Send Document Request from your account section.

The TendersOnTime reference is 17800709. The purchaser document reference is AntiInfect2017.

Browse other tenders from Australia or search by relevant keywords and CPV classification.